^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    NRAS exon 3 mutation

    i
    Other names: NRAS1, HRAS1, N-Ras Protein Part 4, Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog, NRAS, Neuroblastoma RAS Viral Oncogene Homolog, NRAS Proto-Oncogene, GTPase
    Entrez ID:
    4893
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Related tests:
    7d
    Primary large cell neuroendocrine carcinoma of pulmonary artery: a case report and literature review (PubMed, Zhonghua Jie He He Hu Xi Za Zhi)
    The patient subsequently received etoposide plus cisplatin (EP), irinotecan, and third-line combination therapy of serplulimab, anlotinib, and temozolomide. Radical surgery combined with platinum-based chemotherapy constitutes the mainstay of treatment. Molecular testing can provide a basis for personalized therapy, and multiline comprehensive treatment may offer prolonged survival benefits for patients.
    Journal
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    NRAS mutation • NRAS exon 3 mutation
    |
    cisplatin • Focus V (anlotinib) • temozolomide • etoposide IV • irinotecan • Hetronifly (serplulimab)